Drug Trial Radar · NCT05685173
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
107
Planned (sponsor's estimate)
Start
Apr 20, 2023
Primary completion
Feb 16, 2029
Study completion Jan 13, 2030
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jan 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs). The study has 2 parts. The aim of the first part (dose escalation) is to find a safe dose of REGN5837 when given in combination with odronextamab. The goal of the second part (dose expansion) is to use the REGN5837 drug dose found in the first part to see how well REGN5837 in combination with odronextamab works. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)
Conditions
- B-cell Non-Hodgkins Lymphoma (B-NHL)
Interventions
OdronextamabDrug
Administered per the protocol
REGN5837Drug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs) of REGN5837 in combination with odronextamabTime frame: From Cycle 2, Day 1 to Cycle 2, Day 21 (each induction cycle is 21 days)
- Incidence of Treatment-Emergent Adverse Events (TEAEs) of REGN5837 in combination with odronextamabTime frame: Up to approximatively 5 years
- Severity of TEAEs of REGN5837 in combination with odronextamabTime frame: Up to approximatively 5 years
- Incidence of Adverse Events of Special Interest (AESIs) of REGN5837 in combination with odronextamabTime frame: Up to approximatively 5 years
- Severity of AESIs of REGN5837 in combination with odronextamabTime frame: Up to approximatively 5 years
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
University of California Los Angeles (UCLA) Medical Center
Santa Monica, California · Recruiting
Norton Cancer Institute
Louisville, Kentucky · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Harvard Medical School - Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
NYU Langone Health Perlmutter Cancer Center
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
UT Southwestern
Dallas, Texas · Recruiting
Hopital Saint Louis
Paris, France · Recruiting
Gustave Roussy
Villejuif, Île-de-France Region, France · Recruiting
CHU de Bordeaux
Talence, New Aquitaine, France · Recruiting
Amsterdam University Medical Centre, location AMC
Amsterdam, Netherlands · Recruiting
Erasmus Medical Center Rotterdam
Rotterdam, South Holland, Netherlands · Recruiting
Hospital Vall d'Hebron
Barcelona, Spain · Recruiting
University Hospital and Research Institute
Madrid, Spain · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital
Truro, Cornwall, United Kingdom · Recruiting
Southampton General Hospital
Southampton, Hampshire, United Kingdom · Recruiting
Western General Hospital
Edinburgh, Scotland, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.